An FDA advisory panel recommended approval of Optimer’s fidaxomicin, a desperately needed new treatment for the C. diff superbug. But the panel split over whether Optimer can say the drug prevents C. diff recurrence.
Go here to read the rest:
New C. diff Drug OK’d by FDA Panel